CD274 and neoplasm: Most clinical interpretations of PD-L1 status were concordant between the BenchMark XT and PD-L1 IHC 22C3 pharmDx for all five tumor types with regard to negative percentage agreement (NPA; 83–97%), positive percentage agreement (PPA; 86–100%), and overall percentage agreement (OPA; 90–97%); the ICC by tumor type was high (≥0.88).